EZH2 and cancer: The removal of the 4-hydroxy substituents from 2 furnished MC2884 (3, Figure 1), a dual p300/EZH2 inhibitor able to induce cancer-selective cell death in both solid and blood cancers in vitro, ex vivo, and in vivo xenograft models [21,22].